Mutated BRCA genes raise prostate and pancreatic cancer risk
Posted: 28th February 2022
Categories: Industry news, RGCC news
Mutations in BRCA1 and BRCA2 genes increase the risk of breast cancer but may also cause prostate and pancreatic cancers in men, Cambridge University scientists have discovered. After studying the medical history of thousands of families, the team found that 27% of men who carry a BRCA 2 mutation will develop prostate cancer, and those […]
Scientists studying the cell replication process have discovered that damage to DNA during the early stages could potentially create “genomic instability” that could cause cancer. The cutting-edge research into cell replication has implications for future research and could, in time, lead to the development of new strategies for diagnosing and treating cancer. Cells in the […]
Scientists at the Sloan Kettering Institute have engineered a new range of immunotherapies that target not only cancer cells with specific markers but cancer cells surrounding the tumour site. Described by researchers as a “micropharmacy” in the body, the new cells offer hope for those with cancers that evade treatment with immunotherapies or for whom […]
Can brain tumours also be tested with a blood sample?
No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.
Is it possible to measure circulating tumour cells (CTC) in patients with lymphoma or leukaemia?
Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.
Which test is the most comprehensive test?
The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.
How do online consultations work?
Online consultations will give you the opportunity to speak to any member of the RGCC Network at a time and place that is convenient to you. You will be able to choose from a shortlist of clinicians who best suit your needs.
Will online consultations take place via Zoom, Skype, or another method?
Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.
Didn't find an answer to your question? Contact us directly.